177LU-DOTATATE THERAPY IN PROGRESSIVE MENINGIOMA

被引：0
|
作者：
Muether, M. [1 ]
Roll, W. [2 ]
Zinnhardt, B. [2 ]
Schaefers, M. [2 ]
Rahbar, K. [2 ]
Brokinkel, B. [1 ]
Stummer, W. [1 ]
机构：
[1] Univ Hosp Munster, Dept Neurosurg, Munster, Germany
[2] Univ Hosp Munster, Dept Nucl Med, Munster, Germany
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
10.1093/neuonc/noz126.137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P09.05
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [41] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09) : 1337 - 1340
  • [42] Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
    Khan, Jehangir
    Ryden, Tobias
    Van Essen, Martijn
    Svensson, Johanna
    Grudzinski, Joseph
    Bernhardt, Peter
    EJNMMI PHYSICS, 2024, 11 (01):
  • [43] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [44] Safety of 177Lu-DOTATATE administration in a patient with recurrent meningioma complicated by radiation necrosis: a case report
    Ugur Sener
    Muhammed D. Aksu
    Samantha J. Caron
    Paul D. Brown
    William G. Breen
    Eric J. Lehrer
    Geoffrey B. Johnson
    Michael J. Link
    Michael D. Dick
    Hiroaki Takahashi
    Kenneth W. Merrell
    Derek R. Johnson
    Discover Medicine, 1 (1):
  • [45] A multicenter phase 2 randomised controlled trial comparing 177Lu-Dotatate and capecitabine combination treatment with 177Lu-Dotatate in neuroendocrine tumor patients
    Becx, M.
    Hofland, J.
    Nonnekens, J.
    Krenning, E.
    Wyld, D.
    Verburg, F.
    Brabander, T.
    de Herder, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S122 - S123
  • [46] Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
    Katherine I. Wolf
    Abhishek Jha
    Anouk van Berkel
    Damian Wild
    Ingo Janssen
    Corina M. Millo
    M. J. R. Janssen
    Melissa K. Gonzales
    Henri J. K. M. Timmers
    Karel Pacak
    Nuclear Medicine and Molecular Imaging, 2019, 53 : 223 - 230
  • [47] Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
    Wolf, Katherine, I
    AbhishekJha
    van Berkel, Anouk
    Wild, Damian
    Janssen, Ingo
    Millo, Corina M.
    Janssen, M. J. R.
    Gonzales, Melissa K.
    Timmers, Henri J. K. M.
    Pacak, Karel
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 53 (03) : 223 - 230
  • [48] Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
    Urso, Luca
    Nieri, Alberto
    Uccelli, Licia
    Castello, Angelo
    Artioli, Paolo
    Cittanti, Corrado
    Marzola, Maria Cristina
    Florimonte, Luigia
    Castellani, Massimo
    Bissoli, Sergio
    Porto, Francesca
    Boschi, Alessandra
    Evangelista, Laura
    Bartolomei, Mirco
    PHARMACEUTICS, 2023, 15 (04)
  • [49] Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
    Boughdad, Sarah
    Da Mota, Michael
    De Carvalho, Melanie Mendes
    Firsova, Maria
    Prior, John O. O.
    Schaefer, Niklaus
    EUROPEAN JOURNAL OF HYBRID IMAGING, 2022, 6 (01):
  • [50] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
12345